Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX301 in Locally Advanced or Metastatic Solid Tumors
NCT05102214Phase 2Unknown
- Sponsor
- Henlius
- Start
- May 2022
- Primary completion
- Sep 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of hlx301 in solid tumor, non-small cell lung cancer (NSCLC), gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA), head and neck squamous cell carcinoma (HNSCC), sponsored by Henlius. Status: unknown.
02
Drugs
hlx301
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05102214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05102214.